The Hunt for Synthetic Cannabinoids
When it comes to finding synthetic cannabinoids the issues of commercial, legal, and medical normally support the creation of these compounds. In the US, the Food and Drug Administration is in charge of approving new chemicals and must test every active compound with all of the inactive ingredients, which can as an example effect pharmacokinetics. Due to this, you must understand that the different types of cannabis may offer different ratios of CB’s along with other compounds which creates very different formulations of prescription drugs which offer physiological effects. Due to this, the United States Food and Drug Administration cannot evaluate marijuana.
Using FDA language preparations of marijuana in botanical items can be known as dietary supplements and can claim health benefits however, they must include a label stating that this supplement cannot be used to treat or even prevent any type of disease in order to pass FDA regulations.
Many understand that smoking marijuana does cause problems with the respiratory system, but on the other hand, the benefits of cannabis may be not as effective as other therapies that are in place, but it is certain marijuana and THC analogs affect such things as mood, immunity, memory, appetite, nausea, and pain.
Yes, there are other treatments and medication on the market for the abovementioned health issues, there is still a large area for improvement of these products that often offer serious side effects and of course is a huge commercial market.
The challenge for the US Food and Drug Administration is to create a formulation of compounds from marijuana or analogs of marijuana that can be approved. Research escalated once the molecular structure and actions of THC were discovered.
THC mainly targets the Gi protein-coupled receptors, which are known scientifically as CB1 and CB2. Other receptors that are linked to Gi activate these receptors but then block adenylate cyclase from activating, which also prevents signaling AMP through cyclic. CB1 and CB2 are different in the way they distribute so both have distinct roles. CB1 is mainly found in the central nervous system and has the action of suppressing neuronal signaling that is related to appetite, stress, mood, and memory. This receptor was the very first one that was defined to be a part of retrograde neuronal signaling. CB1 is localized on the presynapse with neuronal junctions. This activation can create a lesser release of neurotransmitters. In the majority of cases, normally the signaling goes by the synapse by neurotransmitters that allows synthesis of natural endocannabinoids, along with the secretion into the synapse that leads to retrograde signaling to the original terminate neurotransmitter release.
CB2 is mainly found on immune cells both in the central nervous system and throughout the peripheral vascular system. This Gi linked receptor once activated suppresses the function of the immune cell as well as pain. Even with that said, it is important to understand that CB1 and CB2 often overlap in the actions and distribution CB1 may be found peripherally while CB2 does have neuronal sites and both CB1 and CB2 are associated in nociception.